Vtv Therapeutics (VTVT) said Monday that the US Food and Drug Administration has lifted a clinical hold on its cadisegliatin clinical program, including a phase 3 trial in type 1 diabetes.
The company said it plans to resume the trial after submitting a protocol amendment to reduce its duration from 12 months to 6 months, accelerating the initiation of more extensive pivotal studies for a future marketing submission.
The primary endpoint of assessing certain hypoglycemia rates at 6 months will remain unchanged, Vtv Therapeutics said.
The biopharmaceutical company said the FDA imposed a clinical hold last July due to an unresolved chromatographic signal in a study, and that the hold was lifted after it submitted a response confirming the signal was an experimental artifact.
Shares were over 13% higher in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.